Skip to main content
. Author manuscript; available in PMC: 2014 Sep 28.
Published in final edited form as: Cancer Lett. 2013 Apr 2;338(2):229–238. doi: 10.1016/j.canlet.2013.03.032

Fig. 3. BKM120 decreases the levels of Mcl-1, Bcl-2, and Bcl-XL in dose- (A) and time- (B) dependent fashions along with suppression of Akt phosphorylation (A and C), whereas TRAIL increases Mcl-1 expression (D), which can be abolished by the presence of BKM120 (E).

Fig. 3

A, The given cell lines were treated with the indicated concentrations of BKM120 for 12 h. B, H1299 cells were treated with 2 µM BKM120 for different times as indicated. C, H157 cells were treated with the indicated concentrations of BKM120 or LY294002 for 8 h. D, The given cell lines were treated with the indicated concentrations of TRAIL for 6 h. E, The given cell lines were treated with 2 µM BKM120 alone, 50 ng/ml TRAIL alone and BKM120 plus TRAIL for 6 h. After these treatments, the cells were harvested for preparation of whole-cell protein lysates and subsequent Western blot analysis to detect the indicated proteins.